Analysts Bearish On Valeant With Guidance Cut Predicted
February 27, 2017 at 14:06 PM EST
Mizuho analyst Irina Koffler lowered her price target for Valeant Pharmaceuticals ahead of results, citing concerns over its eroding asset base and lack of organic growth in front of 2017 guidance.
